CBIZ Inc. has released its 2025 State of Healthcare Report, highlighting significant trends impacting employer-sponsored healthcare. The report reveals a notable rise in healthcare costs, with expenses for inpatient, outpatient, and professional care increasing from 2022 to 2024. A key driver of these costs is the growing popularity of GLP-1 drugs, such as Ozempic, which have caused pharmacy spend to surge, now comprising 17% of overall pharmacy expenses, up from 9% in 2022. Additionally, regulatory changes at the state level are expanding employee protections and healthcare accessibility, presenting new compliance challenges for employers. The report provides data-driven insights and strategies for organizations to navigate this complex landscape, emphasizing the importance of innovation and smarter benefits design. For further details, the full report is available on the CBIZ website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.